Details of the Drug
General Information of Drug (ID: DM4NEOU)
Drug Name |
4-(4-Fluoro-benzyl)-piperidine hydrochloride
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-(4-Fluorobenzyl)piperidine hydrochloride; 92822-03-2; 193357-52-7; C12H17ClFN; CHEMBL1204355; 4-(4-Fluoro-benzyl)-piperidine hydrochloride; 4-(4'-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE; Piperidine, 4-[(4-fluorophenyl)methyl]-, hydrochloride; 4-(4-FLUOROBENZYL)PIPERIDINE HCL; AK134910; 4-[(4-fluorophenyl)methyl]piperidine Hydrochloride; 4-(4-FLUOROBENZYL)PIPERIDINE HYDROCHLORIDE Salt; SCHEMBL4247331; KS-00000DOL; CTK7C0359; DTXSID30588780; MolPort-001-778-599; OJKWWANXBGLGQN-UHFFFAOYSA-N; 4NPA-Q05-1; ZX-AV000292; ZX-CM003409
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 |
Molecular Weight | 229.72 | |||||||||||||||||||||
Logarithm of the Partition Coefficient | Not Available | ||||||||||||||||||||||
Rotatable Bond Count | 2 | ||||||||||||||||||||||
Hydrogen Bond Donor Count | 2 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count | 2 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||||||||